GNC Introduces New Products for Ozempic and Wegovy Users
In a bid to cater to a growing market, the General Nutrition Corporation (GNC) has rolled out a specialized line of products targeting users of GLP-1 drugs like Ozempic and Wegovy, commonly prescribed for weight loss.
Under the initiative, GNC has unveiled a dedicated section comprising vitamins, protein shakes, and supplements tailored to complement the needs of individuals on medications such as Ozempic and Wegovy.
In an effort to ensure informed customer service, GNC employees will undergo training on the typical side effects associated with GLP-1s.
With health care providers in the United States reportedly prescribing over 9 million weight-loss drug prescriptions towards the close of 2022, market analysts at JP Morgan anticipate a significant surge in GLP-1 drug users, estimating the number to potentially reach 30 million by the decade’s end.
The move comes as a strategic step for GNC, which faced financial difficulties, filing for bankruptcy in 2020 and subsequently shuttering more than 1,200 of its locations.
